Inclisiran - Alnylam Pharmaceuticals

Drug Profile

Inclisiran - Alnylam Pharmaceuticals

Alternative Names: ALN-60212; ALN-PCSsc; PCSK9si

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; The Medicines Company
  • Class Amino sugars; Antihyperlipidaemics; Drug conjugates; Small interfering RNA
  • Mechanism of Action PCSK9 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia

Most Recent Events

  • 27 Jun 2018 An Independent Data Monitoring Committee (IDMC) recommends continuation of the phase III ORION trials in Hypercholesterolaemia without modification
  • 26 Jun 2018 Adverse events and efficacy data from the phase II ORION-1 trial in Hypercholesterolaemia presented at the American Diabetes Association 78th Scientific Sessions (ADA-2018)
  • 03 May 2018 The Medicines Company plans the ORION-4 cardiovascular outcomes trial in mid-2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top